Cell Line Selection In Novel Protein Therapeutic Development
Source: Bioprocess Online
Lena Tholen, Ph.D, Director of Cell Line and Bioprocess Development at FyoniBio and Meinhard Hasslacher, Ph.D., Head of CMC at SOTIO Biotech weigh in early on important cell line selection considerations for novel protein therapeutics in this segment of the Bioprocess Online Live event Early Process Considerations For Novel Protein Therapeutics.
access the Video!
Log In
Get unlimited access to:
Trend and Thought Leadership Articles
Case Studies & White Papers
Extensive Product Database
Members-Only Premium Content
Welcome Back! Please Log In to Continue.
X
Enter your credentials below to log in. Not yet a member of Bioprocess Online? Subscribe today.
Subscribe to Bioprocess Online
X
Subscribe to Bioprocess Online
This website uses cookies to ensure you get the best experience on our website. Learn more